应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
MRNA Moderna, Inc.
休市中 06-12 16:00:00 EDT
49.91
+0.27
+0.54%
盘后
49.87
-0.04
-0.07%
19:56 EDT
最高
51.75
最低
49.62
成交量
508.12万
今开
49.98
昨收
49.64
日振幅
4.29%
总市值
197.11亿
流通市值
181.32亿
总股本
3.95亿
成交额
2.56亿
换手率
1.40%
流通股本
3.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜Moderna盘中上涨5.57%，报48.31美元
行情直击 · 06-12 01:33
异动解读｜Moderna盘中上涨5.57%，报48.31美元
异动解读 | 获CEPI高达5000万美元埃博拉疫苗研发资助，Moderna盘中大涨5.41%
异动解读 · 06-05
异动解读 | 获CEPI高达5000万美元埃博拉疫苗研发资助，Moderna盘中大涨5.41%
异动解读｜Moderna盘中上涨5.14%，获CEPI高达5000万美元埃博拉疫苗研发资助
行情直击 · 06-05
异动解读｜Moderna盘中上涨5.14%，获CEPI高达5000万美元埃博拉疫苗研发资助
异动解读 | Moderna盘中大涨5.26%，获CEPI高达5000万美元埃博拉疫苗研发资助
异动解读 · 06-04
异动解读 | Moderna盘中大涨5.26%，获CEPI高达5000万美元埃博拉疫苗研发资助
异动解读｜Moderna盘中上涨5.06%，获CEPI高达5000万美元埃博拉疫苗研发资助
行情直击 · 06-04
异动解读｜Moderna盘中上涨5.06%，获CEPI高达5000万美元埃博拉疫苗研发资助
异动解读｜Moderna盘中下跌5.19%，报44.605美元
行情直击 · 06-01
异动解读｜Moderna盘中下跌5.19%，报44.605美元
Moderna获CEPI高达5000万美元资助，用于推进BDBV候选疫苗临床前研发与一期临床试验
美股速递 · 06-01
Moderna获CEPI高达5000万美元资助，用于推进BDBV候选疫苗临床前研发与一期临床试验
美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点
美股速递 · 05-29
美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点
Moderna公司计划于八月中旬前备妥2026-27年度推荐新冠疫苗组分供应
美股速递 · 05-28
Moderna公司计划于八月中旬前备妥2026-27年度推荐新冠疫苗组分供应
异动解读｜Moderna盘中上涨5.07%，报48.04美元
行情直击 · 05-20
异动解读｜Moderna盘中上涨5.07%，报48.04美元
异动解读 | Moderna盘中大跌5.11%，汉坦病毒疫苗概念热度消退及机构质疑商业前景引发回调
异动解读 · 05-20
异动解读 | Moderna盘中大跌5.11%，汉坦病毒疫苗概念热度消退及机构质疑商业前景引发回调
异动解读 | Moderna盘中大跌5.14%，汉坦病毒疫苗概念热度消退叠加机构质疑商业前景引发回调
异动解读 · 05-13
异动解读 | Moderna盘中大跌5.14%，汉坦病毒疫苗概念热度消退叠加机构质疑商业前景引发回调
汉坦病毒疫情带动Moderna(MRNA)盘前扬升3.18% 机构上调目标价至58美元
金吾财讯 · 05-12
汉坦病毒疫情带动Moderna(MRNA)盘前扬升3.18% 机构上调目标价至58美元
个股聚焦：Moderna、英特尔、MidCap Financial Investment
投资观察 · 05-11
个股聚焦：Moderna、英特尔、MidCap Financial Investment
异动解读 | Moderna盘前大涨5.78%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 · 05-11
异动解读 | Moderna盘前大涨5.78%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 | Moderna夜盘大涨6.68%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 · 05-11
异动解读 | Moderna夜盘大涨6.68%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 | Moderna夜盘大涨6.31%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 · 05-11
异动解读 | Moderna夜盘大涨6.31%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价
异动解读 | Moderna盘中大涨16.56%，营收超预期及癌症疫苗数据积极提振股价
异动解读 · 05-08
异动解读 | Moderna盘中大涨16.56%，营收超预期及癌症疫苗数据积极提振股价
Moderna股价大涨逾10%，此前其公布mRNA汉坦病毒疫苗一期临床积极数据
老虎资讯综合 · 05-08
Moderna股价大涨逾10%，此前其公布mRNA汉坦病毒疫苗一期临床积极数据
中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请
智通财经 · 05-08
中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请
加载更多
公司概况
公司名称：
Moderna, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。
发行价格：
--
{"stockData":{"symbol":"MRNA","market":"US","secType":"STK","nameCN":"Moderna, Inc.","latestPrice":49.91,"timestamp":1781294400000,"preClose":49.64,"halted":0,"volume":5081172,"hourTrading":{"tag":"盘后","latestPrice":49.8746,"preClose":49.91,"latestTime":"19:56 EDT","volume":34067,"amount":1700769.5653,"timestamp":1781308562494,"change":-0.0354,"changeRate":-0.000709,"amplitude":0.009818},"delay":0,"changeRate":0.005439161966156245,"floatShares":363290461,"shares":394939400,"eps":-8.14,"marketStatus":"休市中","change":0.27,"latestTime":"06-12 16:00:00 EDT","open":49.98,"high":51.75,"low":49.62,"amount":256415125.625472,"amplitude":0.042909,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.14,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":49.64,"preHourTrading":{"tag":"盘前","latestPrice":49.99,"preClose":49.64,"latestTime":"09:29 EDT","volume":11893,"amount":589629.60791,"timestamp":1781270989071,"change":0.35,"changeRate":0.007051,"amplitude":0.017929},"postHourTrading":{"tag":"盘后","latestPrice":49.8746,"preClose":49.91,"latestTime":"19:56 EDT","volume":34067,"amount":1700769.5653,"timestamp":1781308562494,"change":-0.0354,"changeRate":-0.000709,"amplitude":0.009818},"volumeRatio":0.9934885200511138,"optionData":{"bulkOrders":[{"symbol":"MRNA","call":true,"expireDate":1781236800000,"strike":"48.0","timestamp":1781279016785,"price":2.98,"volume":3497,"amount":1042106,"type":"-"},{"symbol":"MRNA","call":true,"expireDate":1781236800000,"strike":"51.0","timestamp":1781279016785,"price":0.42,"volume":3497,"amount":146874,"type":"+"}]},"impliedVol":0.753,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/MRNA","defaultTab":"news","newsList":[{"id":"1152331316","title":"异动解读｜Moderna盘中上涨5.57%，报48.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152331316","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152331316?lang=zh_cn&edition=full","pubTime":"2026-06-12 01:33","pubTimestamp":1781199200,"startTime":"0","endTime":"0","summary":"6月11日，Moderna盘中上涨5.57%，报48.31美元/股，成交额1.52亿美元。Moderna所在的生物科技行业中，个股中，安进涨4.59%，Propanc Biopharma涨103.73%，Nuvalent涨0.04%，艾伯维公司涨0.42%，吉利德科学涨4.15%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157478361","title":"异动解读 | 获CEPI高达5000万美元埃博拉疫苗研发资助，Moderna盘中大涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157478361","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157478361?lang=zh_cn&edition=full","pubTime":"2026-06-05 00:59","pubTimestamp":1780592375,"startTime":"0","endTime":"0","summary":"Moderna今日盘中股价大幅上涨5.41%，引起了市场的高度关注。消息面上，此次股价异动主要与公司获得重大研发资金支持有关。Moderna宣布与流行病防范创新联盟扩大合作，CEPI承诺提供高达5000万美元的资金，用于支持其针对邦迪布吉奥埃博拉病毒的mRNA候选疫苗的临床前开发及一期临床试验。Moderna作为mRNA医学领域的领导者，其平台在传染病疫苗开发方面持续取得突破，此次获得CEPI的巨额资助，进一步强化了市场对其研发实力和未来增长潜力的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156774512","title":"异动解读｜Moderna盘中上涨5.14%，获CEPI高达5000万美元埃博拉疫苗研发资助","url":"https://stock-news.laohu8.com/highlight/detail?id=1156774512","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156774512?lang=zh_cn&edition=full","pubTime":"2026-06-05 00:56","pubTimestamp":1780592196,"startTime":"0","endTime":"0","summary":"6月4日，Moderna盘中上涨5.14%，报51.58美元/股，成交额1.68亿美元。消息面上，Moderna宣布与流行病防范创新联盟扩大合作，CEPI承诺提供高达5000万美元资金，用于支持其针对本迪布焦埃博拉病毒候选疫苗的临床前开发及一期临床试验。该笔资金将支持临床评估期间的并行制造活动，并为后续大规模二/三期试验奠定基础。Moderna是mRNA医学领域的领导者，其平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗开发成为可能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188861321","title":"异动解读 | Moderna盘中大涨5.26%，获CEPI高达5000万美元埃博拉疫苗研发资助","url":"https://stock-news.laohu8.com/highlight/detail?id=1188861321","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188861321?lang=zh_cn&edition=full","pubTime":"2026-06-04 01:57","pubTimestamp":1780509447,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘中大涨5.26%，引起了市场的广泛关注。消息面上，Moderna宣布与流行病防范创新联盟（CEPI）扩大合作，CEPI承诺提供高达5000万美元资金，用于支持其针对本迪布焦埃博拉病毒候选疫苗的临床前开发及一期临床试验。该笔资金将支持临床评估期间的并行制造活动，并为后续大规模二/三期试验奠定基础。此外，公司此前披露已做好充分准备，预计在八月中旬前完成新冠疫苗组分的生产供应部署，多项管线推进提振市场信心。Moderna是mRNA医学领域的领导者，其平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗开发成为可能。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136570919","title":"异动解读｜Moderna盘中上涨5.06%，获CEPI高达5000万美元埃博拉疫苗研发资助","url":"https://stock-news.laohu8.com/highlight/detail?id=1136570919","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136570919?lang=zh_cn&edition=full","pubTime":"2026-06-04 01:55","pubTimestamp":1780509314,"startTime":"0","endTime":"0","summary":"6月4日，Moderna盘中上涨5.06%，报47.97美元/股，成交额1.33亿美元。消息面上，Moderna宣布与流行病防范创新联盟扩大合作，CEPI承诺提供高达5000万美元资金，用于支持其针对本迪布焦埃博拉病毒候选疫苗的临床前开发及一期临床试验。该笔资金将支持临床评估期间的并行制造活动，并为后续大规模二/三期试验奠定基础。Moderna是mRNA医学领域的领导者，其平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗开发成为可能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199875825","title":"异动解读｜Moderna盘中下跌5.19%，报44.605美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199875825","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199875825?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:24","pubTimestamp":1780323892,"startTime":"0","endTime":"0","summary":"6月1日，Moderna盘中下跌5.19%，报44.605美元/股，成交额9138.91万美元。Moderna所在的生物科技行业中，个股中，Revolution Medicines涨1.16%，Hyperliquid Strategies涨5.06%，Summit Therapeutics跌12.77%，艾伯维公司跌1.76%，Genenta Science涨66.5%。Moderna, Inc.是信使核糖核酸医学领域的领导者，其mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100185800","title":"Moderna获CEPI高达5000万美元资助，用于推进BDBV候选疫苗临床前研发与一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1100185800","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100185800?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:03","pubTimestamp":1780304598,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 宣布，流行病防范创新联盟（CEPI）已承诺提供高达5000万美元的资金，以支持该公司针对布尼亚病毒科（Bunyavirales）的候选疫苗的临床前开发及一期临床试验。\n这笔重要的资金注入将加速该研究性疫苗的研发进程，涵盖从实验室研究到初步人体安全性与免疫反应评估的关键阶段。Moderna将利用其在mRNA技术平台上的专业优势，推进这一针对潜在公共卫生威胁的预防性疫苗的开发工作。\n此次合作凸显了全球卫生组织与生物技术公司携手应对新兴传染病威胁的共同努力。资金的到位为候选疫苗的早期研发提供了关键资源，有望推动其向更广泛的临床测试阶段迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","MRNY","MRNX","BK4548","BK4551","BK4588","BK4532","BK4139","BK4533","BK4534","BK4501","MRNA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139235440","title":"美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1139235440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139235440?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:28","pubTimestamp":1779992883,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的疫苗顾问小组已投票支持一项建议，即在2026-2027年度的新冠疫苗接种活动中，应将疫苗的靶点更新为当前流行的Jn.1谱系Xfg变异株。这一决定标志着公共卫生机构在应对病毒持续演变方面迈出了关键一步。相关企业可能需要据此调整其疫苗成分，以符合新的公共卫生指导。随着病毒变异，疫苗的定期更新已成为新常态，以确保其防护效力。最终决定权仍在FDA，但通常其会采纳顾问委员会的建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","SG9999001176.USD","MRNX","LU1023059063.AUD","IE00BLSP4239.USD","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU0868494617.USD","SG9999003800.SGD","BK4551","LU0058720904.USD","PFE","LU0456855351.SGD","SG9999011175.SGD","BK4532","BK4592","BK4581","BK4599","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","BK4501","LU0170899867.USD","SG9999002232.USD","MRNA","BK4533","LU1057294990.SGD","MRNY","LU0306807586.USD","IE00B19Z3B42.SGD","BK4534","LU1883839398.USD","IE0002270589.USD","BK4548","BK4588","SG9999001176.SGD","BK4547","BK4568","IE00B3T34201.USD","LU0122379950.USD","NVAX","BK4139","LU1066051498.USD","BK4550","LU1894683348.USD","SG9999013999.USD","SG9999002224.SGD","LU0289739699.SGD","LU0225771236.USD","BK4007","LU0225284248.USD","LU0234572021.USD","SGXZ57979304.SGD","LU0321505439.SGD","IE00B19Z3581.USD","BK4585","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158347106","title":"Moderna公司计划于八月中旬前备妥2026-27年度推荐新冠疫苗组分供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1158347106","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158347106?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:19","pubTimestamp":1779970758,"startTime":"0","endTime":"0","summary":"根据最新简报文件披露，Moderna公司已做好充分准备，预计将在八月中旬之前完成针对2026-27年度推荐新冠疫苗组分的生产供应部署。这一时间节点对于确保秋季疫苗接种计划的顺利推进具有关键意义，显示出该公司在应对公共卫生需求方面的前瞻性布局能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4534","BK4501","BK4548","BK4568","BK4533","MRNY","BK4551","BK4585","MRNA","MRNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183369471","title":"异动解读｜Moderna盘中上涨5.07%，报48.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183369471","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183369471?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:27","pubTimestamp":1779287240,"startTime":"0","endTime":"0","summary":"5月20日，Moderna盘中上涨5.07%，报48.04美元/股，成交额5125.11万美元。Moderna所在的生物科技行业中，个股中，Immunovant涨31.27%，Roivant Sciences涨14.85%，再生元制药涨2.02%，安进跌0.28%，艾伯维跌0.33%。Moderna是信使核糖核酸（mRNA）医学领域的领导者，其mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124131106","title":"异动解读 | Moderna盘中大跌5.11%，汉坦病毒疫苗概念热度消退及机构质疑商业前景引发回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1124131106","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124131106?lang=zh_cn&edition=full","pubTime":"2026-05-20 03:59","pubTimestamp":1779220781,"startTime":"0","endTime":"0","summary":"Moderna, Inc.今日盘中股价大幅下挫5.11%，引起了市场关注。消息面上，此前推动公司股价上涨的汉坦病毒疫苗概念热度正在持续消退。投行Evercore ISI发布研报明确指出，汉坦病毒属于低发疾病，市场空间有限，相关事件不太可能为Moderna带来实际营收，股价的大幅波动更多是情绪驱动而非基本面变化。此前，受汉坦病毒疫苗临床数据积极及一季度营收超预期的推动，公司股价曾累计大幅上涨逾20%。当前的回调被市场视为是获利了结压力的延续，反映了市场对相关概念炒作回归理性的态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159058568","title":"异动解读 | Moderna盘中大跌5.14%，汉坦病毒疫苗概念热度消退叠加机构质疑商业前景引发回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1159058568","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159058568?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:58","pubTimestamp":1778680685,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 今日盘中股价大跌5.14%，引起了市场的广泛关注。消息面上，此次股价回调主要源于此前推动股价上涨的汉坦病毒疫苗概念热度消退。投行Evercore ISI发布研报明确指出，汉坦病毒属于低发疾病，市场空间有限，相关事件不太可能为Moderna带来实际营收，股价大幅波动更多是情绪驱动而非基本面变化。此前，受汉坦病毒疫苗临床数据积极及一季度营收超预期推动，公司股价在过去数个交易日内曾累计大幅上涨逾20%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291897","title":"汉坦病毒疫情带动Moderna(MRNA)盘前扬升3.18% 机构上调目标价至58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291897","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634291897?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:55","pubTimestamp":1778576139,"startTime":"0","endTime":"0","summary":"金吾财讯 | Moderna 盘前扬升，截至发稿，最新报54.56美元，上涨3.18%，盘前成交额14.03亿美元。消息面上，独立研究提供商CFRA分析称，在安第斯病毒在邮轮MV Hondius上爆发后，MRNA股票此前已在五天内上涨超过16%。尽管目前尚无针对汉坦病毒的疫苗，但mRNA技术具有包括快速开发、毒株适应性强以及相比传统疫苗可引发更强免疫反应等优势。Moderna正与韩国大学合作开发一种基于mRNA的汉坦病毒疫苗，不过该项目仍处于早期临床前阶段。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300289","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","UDN","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143160264","title":"个股聚焦：Moderna、英特尔、MidCap Financial Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1143160264","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143160264?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:46","pubTimestamp":1778492797,"startTime":"0","endTime":"0","summary":"Moderna 股价在盘前交易中飙升了8%。此前，这家生物医药公司向媒体透露，早在近期一艘邮轮爆发疫情之前，他们就已经启动了针对汉坦病毒的疫苗研发工作。市场对人工智能相关企业的热情持续高涨，推动这两家芯片制造商的股价双双上扬。就在上周五，它们的收盘价均创下了历史新高。据消息，阿波罗全球管理 已就出售其上市业务发展公司 MidCap Financial Investment Corp 进行了谈判。福克斯-A 则是今日计划公布财报的公司之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c3eded8fb3ee9cd51304c05def1e555f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOXA","BK4605","LU2048586759.USD","LU1316542783.SGD","BK4575","LU0203345920.USD","LU1803068979.SGD","BK4139","LU1267930813.SGD","LU0889565833.HKD","IE00B7SZLL34.SGD","BK4553","LU2543165471.USD","MUU","LU2211815571.USD","LU0056508442.USD","LINT","LU0321505868.SGD","BK4548","BK4554","LU0154236417.USD","MUD","LU0157215616.USD","BK4566","LU2458330243.SGD","LU0792757196.USD","LU2089985449.USD","MRNY","BK4602","BK4579","LU1323610961.USD","LU2148611432.USD","LU0321505439.SGD","LU1366333091.USD","LU0889566641.SGD","BK4529","IE00B19Z3581.USD","LU0127658192.USD","MRNA","MU","BK4125","LU0642271901.SGD","MRNX","INTC","04335","LU0081259029.USD","BK4568","BK4515","IE00B19Z3B42.SGD","BK4588","IE0002270589.USD","APO","BK4612","LU0274383776.USD","IE0009356076.USD","LU0719512351.SGD","LU2250418816.HKD","MULL","LU0097036916.USD","LU1852331112.SGD","LU2931357623.SGD","BK4135","LU0109392836.USD","BK4550","BK4551","LU2360106780.USD","IE00B5949003.HKD","BK4543","BK4535","BK4512","IE000M9KFDE8.USD","INTW","LU2286300806.USD","GB00BDT5M118.USD","BK4527","BK4501","LU0203347892.USD","MFIC","BK4534","LU2054465674.USD","BK4532","BK4141","LU0082616367.USD","BK4533","LU2458330169.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106114954","title":"异动解读 | Moderna盘前大涨5.78%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1106114954","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106114954?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:05","pubTimestamp":1778486719,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 今日盘前股价大幅上涨5.78%，引起了市场的广泛关注。首先，公司近日公布了其mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，这验证了其mRNA技术平台应对多种病毒疾病的能力。此外，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。这些因素共同增强了市场对Moderna技术领先地位及未来增长潜力的信心，从而推动了股价在盘前走强。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165332761","title":"异动解读 | Moderna夜盘大涨6.68%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165332761","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165332761?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:27","pubTimestamp":1778484438,"startTime":"0","endTime":"0","summary":"Moderna在今日夜盘交易中大幅上涨6.68%，引起了市场的广泛关注。与此同时，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。这些来自研发管线与财务表现的积极信号，显著增强了投资者对Moderna在mRNA领域技术领先地位及未来增长潜力的信心，从而推动了股价在夜盘时段走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192977429","title":"异动解读 | Moderna夜盘大涨6.31%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1192977429","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192977429?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:03","pubTimestamp":1778457828,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) 在夜盘交易中大幅上涨6.31%，引起了市场的广泛关注。消息面上，公司近日公布了mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，验证了其mRNA平台应对多种病毒疾病的能力。此外，公司公布的一季度营收达到3.89亿美元，远超分析师预期的2.28亿美元。与此同时，其mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据也表现积极，瑞银因此上调了目标价。多重利好因素共振，共同推动了股价的强势表现。这些积极的临床数据和财务表现，进一步增强了市场对Moderna在mRNA技术领域领先地位及其未来增长潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100129801","title":"异动解读 | Moderna盘中大涨16.56%，营收超预期及癌症疫苗数据积极提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1100129801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100129801?lang=zh_cn&edition=full","pubTime":"2026-05-08 23:48","pubTimestamp":1778255333,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA)今日盘中股价大幅上涨16.56%，引起了市场的广泛关注。消息面上，公司此前公布的一季度营收达3.89亿美元，远超分析师平均预期的2.28亿美元，主要受益于国际新冠疫苗销量强劲增长，公司同时重申了全年营收同比增长10%的目标。此外，公司在AACR会议上披露的mRNA个性化肿瘤治疗性疫苗EVM16首次人体数据表现积极，展现出良好的安全性与初步疗效。瑞银近期上调公司目标价，进一步提振了市场信心。综合来看，强劲的财务表现与积极的研发进展共同推动了Moderna股价在今日交易时段内的大幅攀升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144457907","title":"Moderna股价大涨逾10%，此前其公布mRNA汉坦病毒疫苗一期临床积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1144457907","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144457907?lang=zh_cn&edition=full","pubTime":"2026-05-08 23:14","pubTimestamp":1778253284,"startTime":"0","endTime":"0","summary":"Moderna周五早盘股价上涨超10%，此前公司公布了其mRNA汉坦病毒疫苗的一期临床积极数据。这一进展重新提振了投资者对Moderna mRNA产品管线的信心。对于Moderna而言，这项数据验证了其mRNA平台应对多种病毒疾病的能力。汉坦病毒一期数据及其对Moderna mRNA平台的意义Moderna针对其研究性汉坦病毒疫苗候选产品开展的一期临床研究显示，该疫苗耐受性良好，未出现严重安全性信号，并在所有剂量组中均诱导出强劲的抗体反应。","market":"us","thumbnail":"https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Moderna公布mRNA汉坦病毒疫苗一期临床积极数据","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2633459715","title":"中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459715","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633459715?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:57","pubTimestamp":1778245029,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。目前在中国，RSV感染的治疗仍依赖广谱抗病毒药物及对症治疗。因此，迫切需要开发一种有效的RSV疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4548","IND","BK4551","159646","BK4139","MRNA","BK4533","BK4534","MRNY","MRNX","BK4501","02627","BK4588","BK1161","BK4568","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.modernatx.com;www.investors.modernatx.com","stockEarnings":[{"period":"1week","weight":0.0521},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.0504},{"period":"6month","weight":0.6942},{"period":"1year","weight":0.8249},{"period":"ytd","weight":0.6924}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.112326},{"month":2,"riseRate":0.375,"avgChangeRate":0.016129},{"month":3,"riseRate":0.5,"avgChangeRate":0.01856},{"month":4,"riseRate":0.625,"avgChangeRate":0.096502},{"month":5,"riseRate":0.625,"avgChangeRate":0.057817},{"month":6,"riseRate":0.5,"avgChangeRate":-0.014693},{"month":7,"riseRate":0.714286,"avgChangeRate":0.106584},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.089569},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.018964},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032236},{"month":11,"riseRate":0.714286,"avgChangeRate":0.206001},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.033274}],"exchange":"NASDAQ","name":"Moderna, Inc.","nameEN":"Moderna, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Moderna, Inc.,MRNA,Moderna, Inc.股票,Moderna, Inc.股票老虎,Moderna, Inc.股票老虎国际,Moderna, Inc.行情,Moderna, Inc.股票行情,Moderna, Inc.股价,Moderna, Inc.股市,Moderna, Inc.股票价格,Moderna, Inc.股票交易,Moderna, Inc.股票购买,Moderna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}